Advertisement

Topics

Latest "Indinavir Sulfate Abacavir Sulfate Amprenavir Nelfinavir Mesylate Efavirenz" News Stories

15:45 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Indinavir Sulfate Abacavir Sulfate Amprenavir Nelfinavir Mesylate Efavirenz" found in our extensive news archives from over 250 global news sources.

More Information about Indinavir Sulfate Abacavir Sulfate Amprenavir Nelfinavir Mesylate Efavirenz on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Indinavir Sulfate Abacavir Sulfate Amprenavir Nelfinavir Mesylate Efavirenz for you to read. Along with our medical data and news we also list Indinavir Sulfate Abacavir Sulfate Amprenavir Nelfinavir Mesylate Efavirenz Clinical Trials, which are updated daily. BioPortfolio also has a large database of Indinavir Sulfate Abacavir Sulfate Amprenavir Nelfinavir Mesylate Efavirenz Companies for you to search.

Showing "Indinavir Sulfate Abacavir Sulfate Amprenavir Nelfinavir Mesylate Efavirenz" News Articles 1–25 of 171

Sunday 17th February 2019

Global Monohydrate and Heptahydrate Zinc Sulfate Market Research Report 20122024 [Report Updated: 01011970] Prices from USD $1800

The global Monohydrate and Heptahydrate Zinc Sulfate market will reach Volume Million USD in 2017 with CAGR xx% 20192023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the ...


Global Morphine Sulfate Market Research Report 20122024 [Report Updated: 01011970] Prices from USD $1800

The global Morphine Sulfate market will reach Volume Million USD in 2017 with CAGR xx% 20192023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes major pr...

Monday 11th February 2019

Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare

TAIPEI, Taiwan, Feb. 11, 2019 /PRNewswire/ -- An exclusive license agreement for the commercialisation of Foresee Pharmaceutical's (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous depot formulations has been granted to Accord Healthcare. Under the terms of this partnership, Foresee, a Taiwan and US-based biopharma...


Saturday 9th February 2019

Precipitated and Chemical Barium Sulfate Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Precipitated and Chemical Barium Sulfate report provides an independent information about the Precipitated and Chemical Barium Sulfate industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including ...

Wednesday 6th February 2019

Global Neisseria Gonorrhoeae Infections Treatment Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1500

SummaryThe global Neisseria Gonorrhoeae Infections Treatment market will reach Volume Million USD in 2018 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers manufacturing sites, capacity and production, product specifications etc.Major ApplicationMajor TypeKey manufacturers are i...

Tuesday 5th February 2019

FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review regulatory filings for two antibacterial agents. These filings are: (1) a NDA accepted for Priority Review for the combination of relebactam, the company’s investigational beta-lactamase inhibitor, ...

Monday 4th February 2019

INVENTIVA : New results on lanifibranor to be presented at the International Liver Congress 2019

New results on lanifibranor to be presented at the International Liver Congress 2019 New study in NASH concludes that lanifibranor administration combines the beneficial effects of single PPAR agonists, and may have more potent effects on inflammation and disease progression Daix (France), February 4, 2019 - Inventiva S.A. ("Inventiva"), a biopharmaceutical compa...

Friday 1st February 2019

Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in the European Union (EU) for the first-line treatment of adult patients with locally advanced or metasta...

Arch Pharmalabs Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryArch Pharmalabs Ltd Arch Pharmalabs is a healthcare products company that offers pharmaceutical ingredients. The company manufactures, develops and markets active APIs and intermediates. It offers products such as docetaxel anhydrous and trihydrate, amlodipine besylate, perindopril erbumine, trandolapril, timolol maleate, etofylline nicotinate and montelukast sodium products, among others. ...

Merck Announces Fourth-Quarter and Full-Year 2018 Financial Results

Fourth-Quarter 2018 Worldwide Sales Were $11.0 Billion, an Increase of 5 Percent, Including a 3 Percent Negative Impact from Foreign Exchange; Full-Year 2018 Worldwide Sales Were $42.3 Billion, an Increase of 5 Percent, Including a Minimal Impact from Foreign Exchange Fourth-Quarter 2018 GAAP EPS Was $0.69; Fourth-Quarter Non-GAAP EP...

Thursday 31st January 2019

Identification and characterization of synthetic chondroitin-4-sulfate binding peptides in neuronal functions

Wednesday 30th January 2019

Health Logics™ BioCell Collagen® Dietary Supplement NSF Certified

Health Logics™ BioCell Collagen® dietary supplement receives NSF Certified for Sport® Certification. IRVINE, Calif. (PRWEB) January 30, 2019 Health Logics announces that its clinically validated skin, joint, and connective tissue health product, BioCell Collagen®, has earned certification under the NSF Certified for Sport® certification program. NSF International's Certi...

Tuesday 29th January 2019

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux Daix (France), January 29th, 2019 - Inventiva S.A. ("Inventiva"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis ("NASH"), systemic sclerosis and mucopolysaccharidosis ("MPS"), today announces the half-year report of its liquidi...

Global Medical Radiation Shielding Market Will Grow at a CAGR of 5% During 2019-2023| Technavio

Technavio has announced the release of their research report on the global medical radiation shielding market for the forecast period 2019-2023. This medical radiation shielding market analysis report segments the market by application (diagnostic shielding and radiotherapy shielding) and geography (Asia, Europe, North America, and ROW). This press r...

Thursday 24th January 2019

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, efavirenz / emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 05/09/2017, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, efavirenz / emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 05/09/2017, Revision: 3, Status: Authorised

Tuesday 22nd January 2019

Human medicines European public assessment report (EPAR): Efavirenz Teva, efavirenz, HIV Infections, Date of authorisation: 09/01/2012, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Efavirenz Teva, efavirenz, HIV Infections, Date of authorisation: 09/01/2012, Revision: 8, Status: Authorised

Monday 21st January 2019

INVENTIVA : Voting Results from the General Meeting Held on January 18, 2019

Voting Results from the General Meeting Held on January 18, 2019 Daix (France), January 21st, 2019 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced, in accordance with the terms of Article ...

Thursday 17th January 2019

Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery

Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral Opioids DUBLIN - January 17, 2019 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Embrace TDD (targeted drug delivery) clinical study that will evaluate the use of the SynchroMed(TM) II...

Spectrum Pharmaceuticals Sells Marketed Portfolio to Acrotech Biopharma L.L.C. to Focus on New and Innovative Therapies for Cancer Patients

Spectrum will receive $160 million in an upfront cash payment and up to $140 million in regulatory and sales-based milestones Staff size will be reduced by approximately 40 percent with the majority of impacted staff transitioning to Acrotech Spectrum will retain a core group of commercial talent to lead the lau...

Stem Cell/Gel Combo Might Be the Answer in Treating Chemical Burns and Other Serious Eye Injuries

A new study released this week in STEM CELLS Translational Medicine (SCTM) offers hope for anyone who has suffered a serious corneal injury that did not respond well to conventional treatment. DURHAM, N.C. (PRWEB) January 17, 2019 A new study released this week in STEM CELLS Translational Medicine (SCTM) offers hope for anyone who has suffered a serious corneal injury that did not respond well to...

Tuesday 15th January 2019

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study

HLA-B*57:01 screening was added to clinical care guidelines in 2008 to reduce the risk of hypersensitivity reaction from abacavir. The uptake of HLA-B*57:01 screening and incidence of hypersensitivity reaction...

Wednesday 9th January 2019

Correction: Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir–bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death

Tuesday 8th January 2019

Human medicines European public assessment report (EPAR): Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, HIV Infections, Date of authorisation: 31/08/2014, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, HIV Infections, Date of authorisation: 31/08/2014, Revision: 12, Status: Authorised

TransGenic Inc 2342 Financial and Strategic SWOT Analysis Review [Report Updated: 27122018] Prices from USD $125

TransGenic Inc 2342 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your b...

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, efavirenz / emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 08/02/2018, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, efavirenz / emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 08/02/2018, Revision: 1, Status: Authorised


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks